Identification of Potential Drug Targets and Biomarkers for The Imidazoline I2 Receptor

Target Name: Imidazoline I2 receptor (I2)

NCBI ID: P34550

Imidazoline I2 receptor (I2)

Other Name(s): I2B | I2 | I2A

Identification of Potential Drug Targets and Biomarkers for The Imidazoline I2 Receptor

The Imidazoline I2 receptor (I2R) is a G protein-coupled receptor that plays a crucial role in various physiological processes in the body. It is a member of the Imidazoline subfamily, which includes several other G protein-coupled receptors, including the Imidazoline receptor type 2 (I2R-2), which is also known as the 5-HT1A receptor. The I2R is involved in various signaling pathways, including neurotransmitter signaling, pain perception, and blood pressure regulation.

Despite its importance, the I2R is still an untargeted drug target. This lack of targeting has led to a limited understanding of its biology and a lack of available therapeutic options. However, recent studies have identified potential drug targets and biomarkers for the I2R.

I. Structure and Function

The I2R is a G protein-coupled receptor that consists of a transmembrane domain and an intracellular tail. It has a molecular weight of approximately 101 kDa and a pre-peptide length of 23 amino acids. The I2R is involved in the regulation of various physiological processes, including neurotransmitter signaling, pain perception, and blood pressure regulation.

The I2R is a potent modulator of neurotransmitter release and has been shown to play a role in the regulation of neurotransmitter release in the central nervous system. The I2R has been shown to interact with various neurotransmitter systems, including the dopamine, serotonin, and endocannabinoid systems.

In addition to its role in neurotransmitter regulation, the I2R is also involved in the regulation of pain perception. Studies have shown that the I2R plays a role in the regulation of pain modulation in the central nervous system. The I2R has been shown to interact with nociceptive neurons and contribute to the regulation of pain perception.

The I2R is also involved in the regulation of blood pressure. Studies have shown that the I2R has a negative effect on blood pressure and is involved in the regulation of blood pressure in the cardiovascular system. The I2R has been shown to interact with various ion channels, including the voltage-dependent sodium channel (VNa).

II. Potential Drug Targets

A. Small molecule inhibitors

Small molecule inhibitors have been identified as potential drug targets for the I2R. These inhibitors can interact with the I2R and prevent it from interacting with neurotransmitters or other signaling molecules. One such inhibitor is the neurotransmitter agonist N-Acetyl-L-Tyrosine (NAT) , which has been shown to inhibit the I2R and prevent neurotransmitter release.

Another small molecule inhibitor is the DNA-binding molecule pyridostigmine, which has been shown to inhibit the I2R and prevent neurotransmitter release.

B. Biomarkers

Biomarkers are potential indicators of the status of a disease or the presence of a drug target. The I2R has been identified as a potential biomarker for various diseases, including depression, anxiety, and neurodegenerative diseases.

One potential biomarker for the I2R is the level of endocannabinoids in the brain. Endocannabinoids are naturally occurring compounds that resemble the active compounds found in cannabis, including cannabidiol (CBD) and 2-arachidonoylglycerol (2-AG). The I2R is involved in the regulation of endocannabinoid levels in the brain, and changes in endocannabinoid levels have been associated with various neurological disorders, including depression and anxiety.

Another potential biomarker for the I2R is the level of brain-derived neurotrophic factor (BDNF) in the brain. BDNF is a protein that promotes the survival and differentiation of neural cells and is involved in the regulation of various physiological processes, including pain perception and neurotransmission. The I2R is involved in the regulation of BDNF levels in the brain, and changes in BDNF levels have been associated with various neurological disorders, including pain perception and neurodegenerative diseases.

III.Conclusion

The I2R is an untargeted drug target that is involved in various physiological processes in the body. Recent studies have identified potential drug targets and biomarkers for the I2R, including small molecule inhibitors and proteins involved in the regulation of endocannabinoid levels and brain-derived neurotrophic factor levels. Further research is needed to fully understand the biology of the I2R and develop effective therapeutic options.

Protein Name: Imidazoline I2 Receptor (I2)

The "Imidazoline I2 receptor (I2) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Imidazoline I2 receptor (I2) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets